HK1048464B - 作为IL-1β和TNF-α的抑制剂的氨基二苯酮 - Google Patents

作为IL-1β和TNF-α的抑制剂的氨基二苯酮 Download PDF

Info

Publication number
HK1048464B
HK1048464B HK03100584.9A HK03100584A HK1048464B HK 1048464 B HK1048464 B HK 1048464B HK 03100584 A HK03100584 A HK 03100584A HK 1048464 B HK1048464 B HK 1048464B
Authority
HK
Hong Kong
Prior art keywords
phenyl
radical
chloro
phenylamino
group
Prior art date
Application number
HK03100584.9A
Other languages
English (en)
Chinese (zh)
Other versions
HK1048464A1 (en
Inventor
E‧R‧奥托森
E‧R‧奧托森
Original Assignee
里奥药物制品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 里奥药物制品有限公司 filed Critical 里奥药物制品有限公司
Publication of HK1048464A1 publication Critical patent/HK1048464A1/xx
Publication of HK1048464B publication Critical patent/HK1048464B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100584.9A 1999-07-16 2000-07-11 作为IL-1β和TNF-α的抑制剂的氨基二苯酮 HK1048464B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14406299P 1999-07-16 1999-07-16
US60/144,062 1999-07-16
PCT/DK2000/000387 WO2001005751A1 (en) 1999-07-16 2000-07-11 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)

Publications (2)

Publication Number Publication Date
HK1048464A1 HK1048464A1 (en) 2003-04-04
HK1048464B true HK1048464B (zh) 2006-09-01

Family

ID=22506888

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100584.9A HK1048464B (zh) 1999-07-16 2000-07-11 作为IL-1β和TNF-α的抑制剂的氨基二苯酮

Country Status (18)

Country Link
US (1) US6750253B1 (https=)
EP (1) EP1210325B1 (https=)
JP (1) JP2003505363A (https=)
KR (1) KR20020033733A (https=)
CN (1) CN1249025C (https=)
AT (1) ATE278663T1 (https=)
AU (1) AU768878B2 (https=)
CA (1) CA2379293A1 (https=)
CZ (1) CZ2002157A3 (https=)
DE (1) DE60014681T2 (https=)
DK (1) DK1210325T3 (https=)
ES (1) ES2228556T3 (https=)
HK (1) HK1048464B (https=)
HU (1) HUP0201913A3 (https=)
PL (1) PL353644A1 (https=)
PT (1) PT1210325E (https=)
RU (1) RU2247719C2 (https=)
WO (1) WO2001005751A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260081B2 (en) 2000-05-22 2005-07-28 Leo Pharma A/S Benzophenones as inhibitors of il-1beta and tnf-alpha
KR100896667B1 (ko) * 2001-08-28 2009-05-14 레오 파마 에이/에스 신규한 아미노벤조페논 및 이를 포함하는 약제학적 조성물
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
DK1658263T3 (da) * 2003-07-24 2010-09-27 Leo Pharma As Aminobenzophenonforbindelser
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
KR101260236B1 (ko) 2004-12-13 2013-05-06 레오 파마 에이/에스 트리아졸 치환된 아미노벤조페논 화합물
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ME02188B (me) * 2006-02-16 2016-02-20 Anacor Pharmaceuticals Inc Mali molekuli koji sadrže boron kao antiinflamatorni agensi
AU2007225456B2 (en) * 2006-03-16 2013-03-28 Moleac Pte Ltd Combination therapy for treatment of patients with neurological disorders and cerebral infarction
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2206534A1 (de) 2008-10-09 2010-07-14 c-a-i-r biosciences GmbH Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
KR100984851B1 (ko) * 2009-02-05 2010-10-04 주식회사 엠에스엠텍 램프이탈방지형 엘이디 조명
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US10684274B2 (en) 2016-01-12 2020-06-16 The George Washington University, A Congressionlly Chartered Not-For-Profit Corporation Compounds inhibiting Nef-calnexin interaction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones

Also Published As

Publication number Publication date
HUP0201913A2 (en) 2002-10-28
AU5807000A (en) 2001-02-05
CZ2002157A3 (cs) 2002-08-14
KR20020033733A (ko) 2002-05-07
WO2001005751A1 (en) 2001-01-25
ATE278663T1 (de) 2004-10-15
DE60014681T2 (de) 2006-02-02
ES2228556T3 (es) 2005-04-16
JP2003505363A (ja) 2003-02-12
RU2247719C2 (ru) 2005-03-10
AU768878B2 (en) 2004-01-08
CA2379293A1 (en) 2001-01-25
DE60014681D1 (de) 2004-11-11
HK1048464A1 (en) 2003-04-04
CN1249025C (zh) 2006-04-05
US6750253B1 (en) 2004-06-15
PL353644A1 (en) 2003-12-01
EP1210325B1 (en) 2004-10-06
HUP0201913A3 (en) 2002-11-28
EP1210325A1 (en) 2002-06-05
DK1210325T3 (da) 2005-01-31
CN1368957A (zh) 2002-09-11
PT1210325E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
CN1188388C (zh) 作为白介素和肿瘤坏死因子tnf抑制剂的氨基二苯酮
CN1181048C (zh) 作为IL-1β和TNF-α的抑制剂的氨基二苯酮
CN1167667C (zh) 用作IL-1β和TNF-α抑制剂的氨基二苯酮化合物
CN1219764C (zh) 用ω－羧基芳基取代的二苯脲作为raf激酶抑制剂
CN1193003C (zh) 作为IL－1β与TNF－α抑制剂的氨基二苯酮
CN1068879C (zh) 二氢苯并呋喃
CN1249025C (zh) 作为IL－1β和TNF－α的抑制剂的氨基二苯酮
HK1048465B (zh) 作为IL-1β和TNF-α的抑制剂的氨基二苯酮
CN1274669C (zh) 适合用于治疗阿尔茨海默病或老年性痴呆的氟代苯甲酰胺
CN1056684A (zh) 异唑-4-羧酰胺及羟基亚烷基氰乙酰胺，含有这些化合物的药物及它们的应用
CN1028521C (zh) 治疗剂
CN1142493A (zh) 芳基烷基哒嗪酮
CN1231459C (zh) 新型氨基二苯酮
CN1182127C (zh) 新的取代的2-苯并[c]呋喃酮化合物,其制备方法以及包含它们的药物组合物
CN1048030A (zh) 促进人神经生长因子的苯酚衍生物
CN1437605A (zh) 作为肿瘤坏死因子抑制剂的噻吩并二苯并薁化合物
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1552714A (zh) 2-取代苯基-5，7-二烃基-3，7-二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其药物用途
CN1860097A (zh) 酰胺型甲酰胺衍生物
CN1063443C (zh) 新的苯并噻唑衍生物
CN1283622C (zh) 环己基(烷基)－丙醇胺及其制备方法和含有它们的药物组合物
CN1474814A (zh) 取代的苯胺化合物的制备方法
CN1284781C (zh) 具有抗肿瘤活性的多环化合物
CN88102858A (zh) 可用作抗高血压剂的肼衍生物的制备方法
CN1622807A (zh) 用作IgE抑制剂的苯基嘧啶取代的胺

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100711